Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Lillian L. Siu(University Health Network), Azeez Farooki(Ontario Institute for Cancer Research), Afshin Dowlati(University Hospitals of Cleveland), Janet Dancey(Ontario Institute for Cancer Research), Joanna M. Brell(Ontario Institute for Cancer Research), John P. Perentesis(University of Southern California), L. Austin Doyle(Ontario Institute for Cancer Research)
Cited by 231
Related Papers
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
|JAMA Oncology|2016|721
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606